2026 CCC | Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients w/ Advanced NSCLC (NCI 10327): Rationale & Study Design
0% Complete
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Aug 28, 2026
- Last Review
- Aug 28, 2026
- Expires
- Aug 28, 2029
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Accreditation
N/A
